Rotavirus epidemiology and genotype distribution in hospitalised children, Greece, 2008 to 2020: A prospective multicentre study — Dimitra‐Maria Koukou (2022) | RDL Network
Rotavirus epidemiology and genotype distribution in hospitalised children, Greece, 2008 to 2020: A prospective multicentre study
Article 2022 en
Authors
DK
Dimitra‐Maria Koukou
AM
Athanasios Michos
PC
Panagiota Chatzichristou
Abstract
1 min read
Background Two rotavirus (RV) vaccines were licensed in Greece in late 2006 and included in the national immunisation programme in 2012. Aim To study the epidemiology and genotype distribution of RV in children during the post-vaccination period and assess the impact of increased vaccination coverage. Methods In a prospective multicentre hospital-based study, hospitalised children (≤ 16 years) with an RV-positive faecal sample were recruited. Epidemiological and genotyping analyses were performed; periods of low (2008–12) and moderate (2012–20) RV vaccination coverage were compared. Statistical analysis was performed with a chi-squared or Mann–Whitney U test and logistic regression. Results A total of 3,874 children (55.6% male; n = 2,153) with median age of 1.4 years (IQR: 0.5–3.3) were studied during 2008–20. Most RV-infected children were aged ≤ 3 years (72.2%) and hospitalised during December–May (69.1%). Common RV genotypes (G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], G12P[8]) were detected in 92.2% of samples; G-P combinations with prevalence above 1% were G4P[8] (44.1%), G1P[8] (25.4%), G2P[4] (14.9%), G9P[8] (3.5%), G12P[8] (2.2%), G3P[8] (2.1%), other (4.3%) and mixed (3.5%). Of all samples, 97.6% were homotypic or partially heterotypic to vaccines’ genotypes. With moderate vaccination coverage, the seasonal peak was detected earlier, children were older and partially or fully heterotypic genotypes were increased (p < 0.001). Conclusions In the era of moderate RV vaccination coverage in Greece, epidemiology of RV in hospitalised children seemed to change. However, most circulating genotypes remain homotypic or partially heterotypic to RV vaccines. Continuous epidemiological surveillance and genotyping are important to monitor possible changes arising from RV vaccines’ implementation.
Emiel Leegwater, L Dol, Menno R. Bénard, Eveline E. Roelofsen, Nathalie M. Delfos, M. van der Feltz, Femke Mollema, Liesbeth Bosma, Loes E. Visser, Thomas H. Ottens, Nathalie D. van Burgel, M. Sesmu Arbous, Lahssan H. El Bouazzaoui, Rachel Knevel, Rolf H. H. Groenwold, Mark de Boer, Leo G. Visser, Frits R. Rosendaal, Erik B. Wilms, Cees van Nieuwkoop
Joe H. C. Chau, Herman H. Y. Sung, Guichuan Xing, Jacky W. Y. Lam, Ben Zhong Tang, Changhuo Xu, Xinwen Ou, Bingzhe Wang, Hanchen Shen, Junkai Liu, Xueqin Yang, Qingqing Zhou
Discussion(0)
No comments yet. Be the first to comment.